Increased Expression of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Is Correlated with Poor Prognostic Variables in Patients with Thymic Epithelial Tumors

Cancer

Volumn 98, Issue 9, 2003, Pages 1811-1821

  Sogawa, Ken Ichi ^a   Kondo, Kazuya ^a   Fujino, Haruhiko ^a   Takahashi, Yuji ^a   Miyoshi, Takanori ^a   Sakiyama, Shoji ^a   Mukai, Kiyoshi ^b   Monden, Yasumasa ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Invasiveness; Matrix metalloproteinase; Thymoma; Tissue inhibitor of metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; DISEASE ASSOCIATION; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THYMOMA;

EID: 0142243216     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11725     Document Type: Article

References (41)

1. Rosai J, Levine GD. Tumors of the thymus. In: Firminger HI, editor. Atlas of tumor pathology, 2nd series. Washington, DC: Armed Forces Institute of Pathology, 1976: 34-37.
2. Shimosato Y, Mukai K. Tumors of the mediastinum. In: Rosai J, Sobin LH, editors. Atlas of tumor pathology, 3rd series. Washington, DC: Armed Forces Institute of Pathology, 1997: 40-183.
3. Nomori H, Horinouchi H, Kaseda S, et al. Evaluation of malignant grade of thymoma by morphometric analysis. Cancer. 1988;61:982-988.
4. Asamura H, Nakajima T, Mukai K, et al. Degree of malignancy of thymic epithelial tumors in terms of nuclear DNA content and nuclear area. An analysis of 39 cases. Am J Pathol. 1988;133:615-622.
5. Yang WI, Efird JT, Quintanilla-Martinez L, Choi N, Harris NL. Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies. Hum Pathol. 1996;27:70-76.
6. Pich A, Chiarle R, Chiusa L, Palestro G. Argyrophilic nucleolar organizer region counts predict survival in thymoma. Cancer. 1994;74:1568-1574.
7. Hino N, Kondo K, Miyoshi T, Uyama T, Monden Y. High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer. 1997;76:1361-1366.
8. Kondo K, Kinoshita H, Ishikura H, et al. Activation of matrix metalloproteinase-2 is correlated with invasiveness in thymic epithelial tumors. J Surg Oncol. 2001;76:169-175.
9. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
10. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997;17:439-444.
11. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
12. Baker AH, Ahonen M, Kahari VM. Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol. 2000;465:469-483.
13. Rosai J. Histological typing of tumours of the thymus. World Health Organization international histological classification of tumours, 2nd edition. New York: Springer-Verlag, 1999: 9-15.
14. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485-2492.
15. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252-257.
16. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat. 2001;65:55-61.
17. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer. 1995;64:355-359.
18. Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res. 2000;6:3944-3948.
19. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 1995;55:3263-3266.
20. Kusukawa J, Sasaguri Y, Shima I, Kameyama T, Morimatsu M. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study. Am J Clin Pathol. 1993;99:18-23.
21. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst. 1991;83:775-779.
22. Watanabe M, Takahashi Y, Ohta T, Mai M, Sasaki T, Seiki M. Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer. 1996;77:1676-1680.
23. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer. 1996;73:972-978.
24. Kawano N, Osawa H, Ito T, et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol. 1997;28:613-622.
25. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331-5338.
26. Imai K, Ohuchi E, Aoki T, et al. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res. 1996;56:2707-2710.
27. Sato H, Takino T, Kinoshita T, et al. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett. 1996;385:238-240.
28. Visscher DW, Hoyhtya M, Ottosen SK, et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer. 1994;59:339-344.
29. Kumaki F, Matsui K, Kawai T, et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol. 2001;159:2125-2135.
30. Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, Kobayashi M. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol. 1996;26:303-309.
31. Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 1996;56:1654-1659.
32. Yoshizaki T, Maruyama Y, Sato H, Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer. 2001;95:44-50.
33. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113-3119.
34. Shields TW. Thymic tumors. In: Shields TW, editor. Mediastinal surgery. Philadelphia: Lea & Febiger, 1991:153-173.
35. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000;6:2349-2355.
36. Shou Y, Hirano T, Gong Y, et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer. 2001;85: 1706-1712.
37. Sienel W, Hellers J, Morresi-Hauf A, et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer. 2003;103:647-651.
38. Lein M, Jung K, Laube C, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer. 2000;85:801-804.
39. Shimosato Y. Controversies surrounding the subclassification of thymoma. Cancer. 1994;74:542-544.
40. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer. 2002;94:624-632.
41. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer. 2002;95:420-429.